Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 1st Japan-China Meeting of Health Authorities Held
August 16, 2010
- Kyorin: Sales Up 5.9% Driven by Strong Sales of Mainstay Products
August 16, 2010
- Negotiations Being Prolonged between Major Pharmacy Chains and Wholesalers
August 16, 2010
- Novartis Files DNA for COPD Treatment QAB149 in Japan
August 16, 2010
- Tsumura: Sales Up 1.9%
August 16, 2010
- Haruhiko Hirate to Oversee Takeda's Asian Operations
August 16, 2010
- Astellas to Apply for Degarelix for Prostate Cancer within 2010
August 16, 2010
- Kaken: Artz Drives Business
August 16, 2010
- RaQualia Licenses EP4 Antagonist to Maruishi
August 16, 2010
- Application for Hematide to Be Delayed Until 2011 in the US
August 16, 2010
- Nippon Kayaku Aims at Pharm. Sales of \100 Bil. in FY2015
August 16, 2010
- Mochida: Epadel's Sales Down 3%
August 16, 2010
- aRigen Licenses Herpes Treatment ARYS-01 to Centaur of India
August 16, 2010
- Shionogi Obtains Approval for CUVPOSA from US FDA
August 16, 2010
- Asahi Kasei Medical Launches New Cell Culture Fluid Filter
August 16, 2010
- Kissei: Pharmaceutical Sales Up 5.9%
August 16, 2010
- Daiichi Sankyo Begins Tender Offer to Acquire Zenotech
August 16, 2010
- PMDA to Directly Investigate Deaths Reported by Med Institutions
August 16, 2010
- Forteo Offers “Aggressive”Treatment for Osteoporosis: Dr Sowa
August 16, 2010
- Nippon Shinyaku: Cialis Props Up Business
August 16, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…